Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT00110149
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • yttrium Y 90 ibritumomab tiuxetan — RADIATION

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others, such as yttrium Y 90 ibritumomab tiuxetan, find cancer cells and help kill them or carry cancer-killing substances to them without harming normal cells. Giving rituximab together with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with yttrium Y 90 ibritumomab tiuxetan works in treating patients with indolent non-Hodgkin's lymphoma.

Key Dates

Start date
May 31, 2004
Status verified
Oct 2017
Primary completion
May 31, 2012
Completion
Mar 31, 2015

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan

Primary Outcome Measure

Response Rate (Complete Response, Unconfirmed Complete Response, and Partial Response) at 12 Weeks [ Time Frame: 14 weeks ]

Locations (3)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical CenterLebanonNew Hampshire03756-0002-
Vermont Cancer Center at University of VermontBurlingtonVermont05401-3498-

Find similar trials in Boston, MA

By research site
Beth Israel Deaconess Medical Center· Boston, MANorris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center· Lebanon, NHVermont Cancer Center at University of Vermont· Burlington, VT

Related Studies